Abcam Board and Company Secretary

Key to committees/roles:

  • E Executive
  • N Nomination
  • A Audit and Risk
  • R Remuneration
  •   Chair

Murray Hennessy MBA


Appointment: November 2011

  • N
  • R

Background: After an early career as a management consultant in the London, Tokyo and Boston offices of Bain & Company, Murray held a number of senior positions in the restaurant industry with PepsiCo and Yum Brands and also led an internet start-up. Between 2001 and 2004, Murray was the Commercial Director of John Lewis Department Stores, where he pioneered the store's online presence, Following this, Murray became Chief Executive of Avis Europe plc, the car rental company, until 2008. Murray then took the role of Chief Executive of, the online train ticket retailer, until June 2014.

Current external appointments: Murray is chairman of TGIF UK (Thank God It's Friday, UK), Non-Executive Director for SEDCO Holding Company (Saudi Arabia), an advisory board member for River Island, Chairman of Receipt Bank and a Non-Executive Director of Great Wolf Lodges

Skills and experience: Murray has an impressive track record of working internationally in customer-facing industries, as well as significant experience of online businesses. His experience across various consumer-facing sectors where technology plays a key role is valuable to Abcam's digital and customer-facing strategy and his background in management consulting and executive leadership positions supports Abcam's strategy development.

Alan Hirzel MS, MBA

Chief Executive Officer

Appointment: January 2014

  • E

Background: Prior to joining Abcam, Alan spent 14 years with Bain & Company helping companies grow organically and through acquisition. Earlier in his career, he led product innovation efforts for several brands at Kraft Foods. He was trained as a life scientist and published research in plant biochemistry. He also has a passion for social enterprise as a trustee and was founder of the Social Business Trust, providing advice on how to grow and succeed with these enterprises to social entrepreneurs and government organisations globally.

Current external appointments: Alan has no other external appointments.

Skills and experience: Alan brings the Abcam Board an impressive combination of a strong scientific background, global business and leadership experience as well as strong consumer knowledge. Alan has a keen focus on the consumer, helping Abcam's strategic vision to be a successful global business by placing the customer at the heart of the business.

Gavin Wood, BA (Hons) ACA

Chief Financial Officer

Appointment: September 2016

  • E

Background: Gavin is a chartered accountant who started his career in practice in London before moving to Grant Thornton's Thames Valley office. After five years in practice Gavin moved to Unipart Group of Companies where he had a number of roles of increasing responsibility including Global ERP implementations and Business Unit Controller. Gavin then moved into the life sciences sector and spent nearly a decade at Nasdaq quoted Affymetrix Inc in a variety of roles, most recently as EVP & CFO leading the global Finance and Information Technology functions.

Current external appointments: None

Skills and experience: Gavin has over twenty years' experience as an accounting professional with broad and international exposure in a number of sectors and roles including Corporate, Statutory and Operational accounting, Project Management and Investor Relations.

Jonathan Milner, PhD

Deputy Chairman

Appointment: April 1998

Background: Having worked in the life sciences industry for over ten years as an academic researcher, Jonathan identified the market opportunity for supplying high quality antibodies to support protein interaction studies and in 1998 founded Abcam with David Cleevely and Professor Tony Kouzarides.

Current external appointments: Jonathan is a Non-Executive Director of Horizon Discovery Group plc, The Evolution Education Trust, GeoSpock Ltd and Sydicate Room Group Ltd. He is also Chairman of Axol Bioscience Ltd, PhoreMost Ltd, Repositive Limited, Definigen Limited and Cambridge Allergy Ltd. Jonathan holds an executive director position at Meltwind Limited, being a designated member of Meltwind Advisory LLP.

Skills and experience: Jonathan is an experienced entrepreneur and investor and is passionate about supporting UK life science and high-tech start-ups. He has provided considerable investment and support to over 30 companies and has assisted three AIM IPOs.

Louise Patten, MA (Oxon)

Non-executive and Senior Independent Director

Appointment: March 2014

  • N
  • A
  • R

Background: Having started her career in corporate and investment banking, Louise moved into management consultancy and became board director for the Hilton Group. Since then she has served on a succession of multinational listed company boards for more than 20 years as a non-executive Director, senior independent director, chairman of remuneration committee and company chairman at companies including the retailers Marks & Spencer plc, GUS plc and Somerfield plc.

Current external appointments: Louise is currently a Non-Executive Director of the FTSE 100 property group Intu Properties plc, a senior advisor to Bain & Company and a Non-Executive Director to Arthur J. Gallagher Insurance Brokers Limited.

Skills and experience: Louise's highly recognised career in business with her extensive board and corporate governance experience brings Abcam the knowledge and proficiency required to support its strategic growth plans and, whilst doing this, ensures that the Abcam Board is led by a robust governance framework.

Sue Harris, BSc ACMA

Non-executive Director

Appointment: December 2014

  • N
  • A
  • R

Background: A chemist by training, Sue began her career at Ford Motor Co. before moving to oil company Amerada Hess. She subsequently held senior executive roles at Marks & Spencer plc across finance, and latterly as head of corporate development and as corporate treasurer, and Standard Life, where she led the process to float the company in 2006. She then joined Lloyds Banking Group (LBG), where she was Finance Director of, respectively, Cheltenham and Gloucester, LBG's Retail Bank and LBG Group Finance, and latterly Group Audit Director. Previously, Sue was a Non-Executive Director on the board of St. James's Place (representing LBG) and a member of the audit and remuneration committees of the British Bankers' Association. She was previously chair of trustees for KCP Youth and during a ten-year association with Mencap chaired both the finance and audit committees.

Current external appointments: Sue is an independent Non-Executive Director of Bank of Ireland UK, a member of the Audit and Assurance Council and Codes and Standards Committee of the Financial Reporting Council, a Non-Executive Director of Schroder & Co. Limited and a member of the Audit and Risk Committee of Schroder Wealth Management Division.

Skills and experience: Sue has over 30 years of financial and commercial experience. Along with her corporate board experience and scientific background, Sue brings a wealth of finance and commercial skills that strengthens the Abcam Board in its current growth strategy as well as being the ideal person to chair the Audit and Risk Committee.

Mara Aspinall, MBA

Non-executive Director

Appointment: September 2015

  • N
  • R

Background: Mara was the President and Chief Executive Officer of Ventana Medical Systems, the Tissue Diagnostics Division of the Roche Group. While at Ventana, she led the company to increased market leadership worldwide and primacy in companion diagnostics. Previously, Mara spent twelve years at Genzyme Corporation (now part of Sanofi) where she was the President of Genzyme Genetics and Genzyme Pharmaceuticals. She was also the founder and chief executive officer of On-Q-ity, a circulating tumour cells company. Mara is co-founder of EPEMED (European Personalized Medicine Association) and the International School of Biomedical Diagnostics at Arizona State University and Dublin City University, the only school dedicated to the study of diagnostics as an independent discipline. She is a fellow of the American Institute for Medical and Biological Engineering.

Current external appointments: Mara is the Chief Executive Officer of Health Catalysts, Executive Chairman of GenePeeks Inc. Director of Safeguard Scientifics Inc., Director of Castle Biosciences, a Director of Blue Cross Blue Shield Arizona, Director of SenesTech Inc., a Director of CA Therapeutics and is on the non-fiduciary advisory boards of ProMIS Neurosciences, Inc., Slone Partners and Greybird Ventures.

Skills and experience: Mara has considerable international experience in the biotechnology and diagnostics industries with small and large, public and private companies. Mara's specific focus areas are in her operational expertise including acquisition integration, global manufacturing, quality systems and strategic marketing. Her knowledge of the diagnostics industry is helpful in establishing Abcam's business in this sector.

Suzanne Smith, LLB (Hons) MBA

Company Secretary & Chief Legal Officer

Appointment: July 2015

Background: Before joining Abcam, Suzanne was Executive Director, Legal at Actavis plc where she was responsible for the leadership of the legal function internationally (ex-Americas). Previous positions include Legal Director at Genzyme Therapeutics Ltd, General Counsel and Company Secretary at Phoqus Pharmaceuticals plc and Group Legal Counsel and Company Secretary at LGC Ltd, together with positions at SmithKline Beecham and Aventis.

Skills and experience: Suzanne is a qualified solicitor with over 20 years global legal, business and leadership experience within the life sciences industry. Her experience in legal and company secretarial roles brings Abcam additional knowledge and skills in corporate governance.

About Abcam

Abcam is a producer and marketer of high quality protein research tools. These tools enable life scientists to analyse components of living cells at the molecular level which is essential in a wide range of fields including drug discovery, diagnostics, and basic research.

Read more +

Abcam Products

As an innovator in reagents and tools, Abcam offers highly validated binders and assays to address important targets in critical biological pathways.

Read more +

Investor Information

Abcam is listed on the AIM market of the London Stock Exchange under the ticker ABC, and our investors' centre includes a range of information on our company, including our news, financial reports and investor contacts

Read more +

Abcam News

We provide updates on our commercial and financial progress through regular press releases which can be accessed through the Company's media centre.

Read more +